BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600 + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12028 In this phase 2 clinical trial, the efficacy of RAF inhibitor tovorafenib (DAY-101) was investigated in patients between the ages of 6 months and 25 years, with pediatric low-grade gliomas harbouring … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF Fusion5
Everolimus + TrametinibCombination	Childhood Low Grade Glioma	Predictive	D	Supports Sensitivity Response	2	accepted	EID7199 This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC	civic
Selumetinib	Childhood Pilocytic Astrocytoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID8943 In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic
Sorafenib + VemurafenibSubstitutes	Childhood Pilocytic Astrocytoma
BRAF V600E16
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF V6005
Vemurafenib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5905 Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient wa… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID1411 The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafen… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma
BRAF L597S2
MEK Inhibitor REC-4881	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1460 Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diame… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1459 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF D594G2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6001 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6002 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF G469E2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6003 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6004 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis af… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF D594A1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1454 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF K483M1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1457 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF D594V1
Sorafenib + TrametinibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1456 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF L597V1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1463 Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response wi… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1570 Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intro… (full text at CIViC) PMID 26072686 · Menzies et al., 2015 · Open in CIViC	civic
BRAF L597Q2
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID4905 Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response a… (full text at CIViC) PMID 24933606 · Bowyer et al., 2014 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1461 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID13150 A 42 year old male patient with stage III cutaneous melanoma harboring an AGAP3::BRAF fusion was treated with the MEK inhibitor trametinib after prior pembrolizumab and experienced a response lasting … (full text at CIViC) PMID 35871080 · Moran et al., 2022 · Open in CIViC	civic
BRAF V600K1
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID4181 In a phase 3 clinical trial (NCT01597908) involving 704 patients with metastatic melanoma harboring BRAF V600 mutations, a subgroup analysis of patients with V600K mutations showed an objective respon… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID1416 Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression o… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
BRAF L597R1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1458 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF K601E1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1462 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF T599dup1
Dabrafenib + TrametinibCombination	Ganglioglioma	Predictive	C	Supports Sensitivity Response	3	accepted	EID9789 A pediatric case of ganglioglioma was previously reported (PMID: 29434027) to harbor a BRAF p.T599dup variant (observed at VAF of 5.2%). The patient had a partial resection and was then treated with V… (full text at CIViC) PMID 33637608 · Miller et al., 2021 · Open in CIViC	civic
BRAF Exon 15 Mutation2
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID4121 This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal… (full text at CIViC) PMID 27371698 · Ben-Ami et al., 2016 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	1	accepted	EID4605 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
BRAF G596C1
Dabrafenib + TrametinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1738 Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC) PMID 28947956 · Noeparast et al., 2017 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Sorafenib	US FDA	—	Efficacy supplement 2007-11-16 (see label)	approved	Nov 16, 2007	openfda
Sorafenib	US FDA	Differentiated Thyroid Gland Carcinoma	Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment	approved	Dec 1, 2005	openfda
Sorafenib	US FDA	Renal Cell Carcinoma	Advanced renal cell carcinoma	approved	Dec 1, 2005	openfda
Sorafenib	US FDA	Hepatocellular Carcinoma	NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 401–450 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04020809	Neoadjuvant Atezolizumab in Cutaneous Melanoma	active not recruiting	Phase 1	20	The Methodist Hospital Research InstituteOTHER	1	Mar 9, 2026	clinicaltrials
NCT05116189	Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	active not recruiting	Phase 3	643	Merck Sharp & Dohme LLCINDUSTRY	25	Mar 9, 2026	clinicaltrials
NCT05846867	A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	170	AkesoINDUSTRY	1	Mar 4, 2026	clinicaltrials
NCT06951503	AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer	recruiting	Phase 3	560	AkesoINDUSTRY	1	Mar 4, 2026	clinicaltrials
NCT07449754	Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma	recruiting	Phase 2	45	Hanmi Pharmaceutical Company LimitedINDUSTRY	1	Mar 4, 2026	clinicaltrials
NCT04094688	Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer(SOLARIS)	active not recruiting	Phase 3	455	Alliance for Clinical Trials in OncologyOTHER	2	Mar 3, 2026	clinicaltrials
NCT02721459	XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	active not recruiting	Phase 1	26	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Mar 2, 2026	clinicaltrials
NCT06346067	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	active not recruiting	Phase 3	78	Erasca, Inc.INDUSTRY	9	Feb 27, 2026	clinicaltrials
NCT07033819	Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib	recruiting	Phase 2	48	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Feb 27, 2026	clinicaltrials
NCT07435584	Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)(EVER-RECODE)	not yet recruiting	Phase 1 / Phase 2	38	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	0	Feb 27, 2026	clinicaltrials
NCT03774732	PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer(NIRVANA-LUNG)	active not recruiting	Phase 3	327	UNICANCEROTHER	2	Feb 25, 2026	clinicaltrials
NCT04430738	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	active not recruiting	Phase 2	40	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	2	Feb 24, 2026	clinicaltrials
NCT04666272	Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection	active not recruiting	—	78	Novartis PharmaceuticalsINDUSTRY	1	Feb 19, 2026	clinicaltrials
NCT04868877	Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	active not recruiting	Phase 1 / Phase 2	194	Merus B.V.INDUSTRY	9	Feb 19, 2026	clinicaltrials
NCT07063212	A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)	recruiting	Phase 2	40	Memorial Sloan Kettering Cancer CenterOTHER	1	Feb 19, 2026	clinicaltrials
NCT06754501	A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary	active not recruiting	Phase 2	4	M.D. Anderson Cancer CenterOTHER	1	Feb 18, 2026	clinicaltrials
NCT05171660	Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer	active not recruiting	Phase 3	446	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Feb 17, 2026	clinicaltrials
NCT07407465	Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA)	recruiting	Phase 2	42	Gruppo Oncologico del Nord-OvestOTHER	4	Feb 17, 2026	clinicaltrials
NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	Phase 1	30	Rina PlattnerOTHER	1	Feb 13, 2026	clinicaltrials
NCT06353646	XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer	recruiting	N/A	28	Wu WenmingOTHER	1	Feb 13, 2026	clinicaltrials
NCT06731270	Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy	recruiting	Phase 2	20	Emory UniversityOTHER	1	Feb 12, 2026	clinicaltrials
NCT02152631	A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER)	active not recruiting	Phase 3	453	Eli Lilly and CompanyINDUSTRY	21	Feb 6, 2026	clinicaltrials
NCT07391566	LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation	not yet recruiting	Phase 1 / Phase 2	99	Luye Pharma Group Ltd.INDUSTRY	1	Feb 6, 2026	clinicaltrials
NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	active not recruiting	Early Phase 1	14	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Feb 5, 2026	clinicaltrials
NCT06268015	Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo)	active not recruiting	Phase 2	16	Nicholas DeVito, MDOTHER	1	Feb 5, 2026	clinicaltrials
NCT07389265	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM)	recruiting	Phase 3	480	University of Campania Luigi VanvitelliOTHER	2	Feb 5, 2026	clinicaltrials
NCT06697197	A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	413	Bristol-Myers SquibbINDUSTRY	9	Feb 3, 2026	clinicaltrials
NCT06440850	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation	recruiting	Phase 2	21	City of Hope Medical CenterOTHER	1	Feb 2, 2026	clinicaltrials
NCT04854668	A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer	active not recruiting	Phase 3	748	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Jan 30, 2026	clinicaltrials
NCT04467723	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	recruiting	Phase 1 / Phase 2	25	University of Kansas Medical CenterOTHER	1	Jan 28, 2026	clinicaltrials
NCT06208657	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	recruiting	Phase 1 / Phase 2	90	Australian & New Zealand Children's Haematology/Oncology GroupOTHER	2	Jan 28, 2026	clinicaltrials
NCT07370818	To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer	not yet recruiting	Phase 2	81	Onconic Therapeutics Inc.INDUSTRY	1	Jan 27, 2026	clinicaltrials
NCT04137107	Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer	active not recruiting	Phase 2 / Phase 3	220	Alliance for Clinical Trials in OncologyOTHER	2	Jan 26, 2026	clinicaltrials
NCT05601973	Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung)	active not recruiting	Phase 2	60	ETOP IBCSG Partners FoundationNETWORK	6	Jan 21, 2026	clinicaltrials
NCT02411448	A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY)	active not recruiting	Phase 3	545	Eli Lilly and CompanyINDUSTRY	14	Jan 16, 2026	clinicaltrials
NCT03875781	Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer(NORAD01)	recruiting	Phase 3	540	Assistance Publique - Hôpitaux de ParisOTHER	1	Jan 15, 2026	clinicaltrials
NCT00335816	Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer	active not recruiting	Phase 2	248	Memorial Sloan Kettering Cancer CenterOTHER	2	Jan 14, 2026	clinicaltrials
NCT03977233	Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer	recruiting	Phase 2	45	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Jan 13, 2026	clinicaltrials
NCT04689347	5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	recruiting	Phase 1 / Phase 2	27	Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER	1	Jan 12, 2026	clinicaltrials
NCT07330596	QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC	recruiting	Phase 2	96	Anhui Provincial Cancer HospitalOTHER	1	Jan 9, 2026	clinicaltrials
NCT06838338	JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC	active not recruiting	Phase 1	30	Jian LiOTHER	1	Jan 8, 2026	clinicaltrials
NCT04161755	Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery	active not recruiting	Phase 1	29	Memorial Sloan Kettering Cancer CenterOTHER	1	Jan 7, 2026	clinicaltrials
NCT05504252	METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2)	active not recruiting	Phase 2	80	University Hospital, AkershusOTHER	1	Jan 7, 2026	clinicaltrials
NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect)	active not recruiting	Phase 2	26	Emory UniversityOTHER	1	Jan 5, 2026	clinicaltrials
NCT04367311	Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)	active not recruiting	Phase 2	100	Nasser HannaOTHER	1	Jan 2, 2026	clinicaltrials
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 3	1,052	National Cancer Institute (NCI)NIH	3	Dec 30, 2025	clinicaltrials
NCT06512051	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer	recruiting	Phase 1 / Phase 2	248	Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY	1	Dec 23, 2025	clinicaltrials
NCT03869892	Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE)	active not recruiting	Phase 3	856	Institut de Recherches Internationales ServierOTHER	25	Dec 22, 2025	clinicaltrials
NCT06971744	Autophagy Maintenance (AUTOMAIN)	recruiting	Phase 2	38	Medical University of South CarolinaOTHER	1	Dec 22, 2025	clinicaltrials
NCT06102057	PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC(PACCELIO)	recruiting	Phase 2	110	TheraOpOTHER	2	Dec 17, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)